LONDON, UK: Syncona Ltd has committed $25 million (£19 million) to Quell Therapeutics, a world leader in developing engineered T-regulatory (Treg) cell therapies for serious medical conditions driven by the immune system, in an up to $156 million (£117 million) Series B financing. Syncona co-led the financing round alongside specialist global institutional investors Jeito Capital,…